January 20, 2023 11:03 AM EST
News Briefing

Seagen's Tukysa la­bel ex­pand­ed; ADARx gets $46M script for RNA tri­al

Kyle LaHucik

Senior Reporter

Paul Schloesser

Associate Editor

Seagen just scored an­oth­er ap­proval for one of its lead drugs.

Tukysa won ac­cel­er­at­ed ap­proval from the FDA on Thurs­day to be used in com­bi­na­tion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

Will CRISPR mat­ter?

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times